MAPT and Alzheimer disease: Masitinib (28) is a potent and selective tyrosine kinase inhibitor targeting multiple aspects of AD, including inhibition of microglia and mast cell activation, modulation of Aβ and tau protein signaling pathways, and prevention of synaptic damage.475 It is currently undergoing a phase III clinical trial (NCT05564169).